← Back to Search

Blood Product

Transfusion Strategies for Anemia (EToF Trial)

N/A
Recruiting
Research Sponsored by University of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥ 18 years
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6mwt will be measured at admission to the hospital during the index hospitalization and 7 days after hospital discharge.
Awards & highlights

EToF Trial Summary

This trial is testing whether restrictive transfusions (at Hb<7g/dL) are as effective as liberal transfusions (at Hb<9g/dL) in reducing fatigue and improving activity levels in hospitalized patients with anemia.

Who is the study for?
This trial is for adults over 18 with anemia who are hospitalized at the University of Chicago and have a hemoglobin level below 9g/dL. It's not for those who refuse blood transfusions, can't do follow-ups after leaving the hospital, have sickle cell anemia, are only getting palliative care, or are brain dead.Check my eligibility
What is being tested?
The study compares two blood transfusion strategies in anemic patients: one gives transfusions when hemoglobin drops below 9g/dL (liberal), and the other below 7g/dL (restrictive). We're checking how tired they feel and their activity levels right after treatment and a week later.See study design
What are the potential side effects?
Red blood cell transfusions may cause allergic reactions, fever, iron overload in long-term cases, lung injury from fluid overload (TACO), or immune system reactions.

EToF Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

EToF Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~fatigability will be measured at admission to the hospital during the index hospitalization and 7 days after hospital discharge.
This trial's timeline: 3 weeks for screening, Varies for treatment, and fatigability will be measured at admission to the hospital during the index hospitalization and 7 days after hospital discharge. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in self-reported fatigability level
Secondary outcome measures
Change in 6 Minute Walk Test (6MWT) distance
Change in self-reported activity level
Change in self-reported fatigue level

EToF Trial Design

2Treatment groups
Active Control
Group I: Liberal Transfusion ArmActive Control1 Intervention
Patient's in the liberal transfusion arm will receive a 1 unit RBC transfusion following randomization and will re-ceive blood in additional 1 unit increments until their Hb is above 9g/dL. At any point during the patient's hospital-ization if their Hb subsequently falls below 9g/dL, they will again be transfused to maintain a Hb>9g/dL, and this will be maintained throughout their hospitalization.
Group II: Restrictive Transfusion ArmActive Control1 Intervention
Patients in the restrictive transfusion arm will receive transfusion if their Hb concentration falls below 7g/dL. RBC's will be administered 1 unit at a time and enough blood will be given to increase patient's Hb to above 7g/dL.

Find a Location

Who is running the clinical trial?

University of ChicagoLead Sponsor
997 Previous Clinical Trials
816,950 Total Patients Enrolled

Media Library

Red blood cell transfusion (Blood Product) Clinical Trial Eligibility Overview. Trial Name: NCT04920045 — N/A
Anemia Research Study Groups: Liberal Transfusion Arm, Restrictive Transfusion Arm
Anemia Clinical Trial 2023: Red blood cell transfusion Highlights & Side Effects. Trial Name: NCT04920045 — N/A
Red blood cell transfusion (Blood Product) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04920045 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment searching for new participants at present?

"Affirmative. Data on clinicaltrials.gov affirms that this study, which was first publicized in February of 2022, is still actively searching for participants. There are 748 available slots at a single medical facility."

Answered by AI

What is the overall participation rate for this experiment?

"Affirmative. The online record on clinicaltrials.gov confirms that this research has been luring participants since February 1st 2022 and was most recently updated May 16th 2022. Altogether, 748 subjects are expected to join the study from a single trial centre."

Answered by AI
~274 spots leftby Jul 2025